Skip to main content
. 2021 May 3;21:196. doi: 10.1186/s12886-021-01954-y

Table 2.

Evaluation of the secondary outcomes by between-group analyses

Secondary outcomes Group Time-points
Week 1
mean ± s.d.
Month 1
mean ± s.d.
Month 3
mean ± s.d.
Month 6
mean ± s.d.
BVCA (logMAR) A 0.50 ± 0.51 0.26 ± 0.16 0.20 ± 0.21 0.19 ± 0.18
B 0.55 ± 0.32 0.37 ± 0.26 0.31 ± 0.24 0.28 ± 0.23
p-value n.s. n.s. n.s. n.s.
IOP (mmHg) A 17.7 ± 7.0 16.1 ± 2.4 15.9 ± 3.0 15.5 ± 2.6
B 13.7 ± 3.3 15.4 ± 4.9 14.9 ± 3.3 14.2 ± 3.5
p-value < 0.001 n.s. n.s. n.s.
CMT (μm) A 279 ± 26 270 ± 26 270 ± 25
B 278 ± 30 316 ± 118 297 ± 91
p-value n.s. 0.01 n.s.
LOCS III A 0.35 ± 0.75 0.54 ± 0.90 0.73 ± 1.15 1.31 ± 1.74

p-value

vs baseline

n.s n.s n.s 0.003

BCVA Best-corrected visual acuity, IOP Intraocular pressure, CMT Central macular thickness (by Optical Coherence Tomography), LOCS III Lens Opacities Classification System III scale